Rallybio Corp (RLYB)

Rallybio Corp experienced significant insider trading activity recently, characterized by substantial net buying. ADAR1 Capital Management, LLC executed eleven purchase transactions totaling over $2 million. These acquisitions occurred amidst a 15.4% stock price increase over the last quarter, following a positive earnings report where the company outperformed expectations by 14.8%.
Ticker: RLYB Exchange: NSM


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Rallybio Corp. Upgrade to see score, net flow, insiders and the full signal context.

Top insiders
Trades
Buy 19 May 2026
Value US$3,996,285.19 | Price 390.16 | Shares 38,872 (+25.0%)
Buy 19 May 2026
Value US$523,402.30 | Price 494.42 | Shares 26,474 (+8.9%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2026-05-20 2026-05-19 B Purchase Large shareholder
38,872 +25.0%
390.16
US$3,996,285
38,872 +25.0% 390.16 US$3,996,285
2026-05-20 2026-05-19 B Purchase Large shareholder
26,474 +8.9%
494.42
US$523,402
26,474 +8.9% 494.42 US$523,402
2026-05-20 2026-05-18 B Purchase Large shareholder
18,474 -6.9%
398.92
US$1,669,074
18,474 -6.9% 398.92 US$1,669,074
2026-05-15 2026-05-15 B Purchase Large shareholder
200 +0.0%
13.95
US$2,790
200 +0.0% 13.95 US$2,790
2026-05-15 2026-05-15 B Purchase Large shareholder
100 +0.0%
13.80
US$1,380
100 +0.0% 13.80 US$1,380
2026-05-15 2026-05-13 B Purchase Large shareholder
75,178 +9.0%
14.00
US$1,052,492
75,178 +9.0% 14.00 US$1,052,492
2026-05-15 2026-05-13 B Purchase Large shareholder
4,081 +0.5%
13.80
US$56,315
4,081 +0.5% 13.80 US$56,315
2026-05-13 2026-05-12 B Purchase Large shareholder
800 +0.1%
13.83
US$11,063
800 +0.1% 13.83 US$11,063
2026-05-13 2026-05-11 B Purchase Large shareholder
19,900 +2.5%
14.00
US$278,600
19,900 +2.5% 14.00 US$278,600
2026-05-13 2026-05-11 B Purchase Large shareholder
25,000 +3.2%
14.00
US$350,000
25,000 +3.2% 14.00 US$350,000
2026-05-13 2026-05-11 B Purchase Large shareholder
5,100 +0.7%
14.00
US$71,392
5,100 +0.7% 14.00 US$71,392
2026-05-06 2026-05-05 B Purchase Large shareholder
35,101 +4.7%
14.00
US$491,260
35,101 +4.7% 14.00 US$491,260
2026-05-06 2026-05-04 B Purchase Large shareholder
116,904 +18.6%
13.97
US$1,633,207
116,904 +18.6% 13.97 US$1,633,207
2026-05-06 2026-05-04 B Purchase Large shareholder
3,900 +0.6%
13.90
US$54,201
3,900 +0.6% 13.90 US$54,201
2026-02-23 2026-02-23 S Sale

Chief Financial Officer

Officer
789 -16.1%
5.06
US$3,992
789 -16.1% 5.06 US$3,992
2023-03-16 2023-03-14 B Purchase

See Remarks

Officer
5,000 +inf%
5.21
US$26,050
5,000 +inf% 5.21 US$26,050
2023-03-09 2023-03-07 S Sale Non-Executive Director
100,000 -4.0%
8.20
US$820,000
100,000 -4.0% 8.20 US$820,000
2023-03-09 2023-03-07 S Sale Large shareholder
100,000 -4.0%
8.20
US$820,000
100,000 -4.0% 8.20 US$820,000
2022-06-07 2022-06-03 S Sale Non-Executive Director Large shareholder
50,329 -3.9%
12.50
US$629,112
50,329 -3.9% 12.50 US$629,112
2022-06-07 2022-06-03 S Sale Non-Executive Director Large shareholder
99,671 -3.9%
12.50
US$1,245,888
99,671 -3.9% 12.50 US$1,245,888
2022-06-07 2022-06-03 S Sale Large shareholder
99,671 -3.9%
12.50
US$1,245,888
99,671 -3.9% 12.50 US$1,245,888
2022-06-07 2022-06-03 S Sale Large shareholder
50,329 -3.9%
12.50
US$629,112
50,329 -3.9% 12.50 US$629,112
2022-05-25 2022-05-23 S Sale Non-Executive Director Large shareholder
33,553 -2.5%
13.00
US$436,189
33,553 -2.5% 13.00 US$436,189
2022-05-25 2022-05-23 S Sale Non-Executive Director Large shareholder
66,447 -2.5%
13.00
US$863,811
66,447 -2.5% 13.00 US$863,811
2022-05-25 2022-05-23 S Sale Large shareholder
66,447 -2.5%
13.00
US$863,811
66,447 -2.5% 13.00 US$863,811
2022-05-25 2022-05-23 S Sale Large shareholder
33,553 -2.5%
13.00
US$436,189
33,553 -2.5% 13.00 US$436,189
2022-03-23 2022-03-21 B Purchase

See Remarks

Officer
3,000 +6.8%
8.04
US$24,120
3,000 +6.8% 8.04 US$24,120
2022-02-10 2022-02-08 S Sale Non-Executive Director
70,461 -5.0%
13.05
US$919,516
70,461 -5.0% 13.05 US$919,516
2022-02-10 2022-02-08 S Sale Non-Executive Director
139,539 -5.0%
13.05
US$1,820,984
139,539 -5.0% 13.05 US$1,820,984
2022-02-10 2022-02-08 S Sale Large shareholder
139,539 -5.0%
13.05
US$1,820,984
139,539 -5.0% 13.05 US$1,820,984
2022-02-10 2022-02-08 S Sale Large shareholder
70,461 -5.0%
13.05
US$919,516
70,461 -5.0% 13.05 US$919,516
2022-01-21 2022-01-19 B Purchase

See Remarks

Officer
1,400 +3.3%
8.70
US$12,180
1,400 +3.3% 8.70 US$12,180
2022-01-14 2022-01-13 B Purchase

See Remarks

Officer
807 +0.1%
9.62
US$7,763
807 +0.1% 9.62 US$7,763
2022-01-14 2022-01-13 B Purchase

See Remarks

Officer
4,193 +0.6%
9.06
US$37,989
4,193 +0.6% 9.06 US$37,989
2022-01-14 2022-01-12 B Purchase

See Remarks

Officer
5,000 +0.7%
10.55
US$52,750
5,000 +0.7% 10.55 US$52,750
2022-01-12 2022-01-11 B Purchase

Chief Executive Officer

Executive Director
4,496 +1.6%
10.65
US$47,882
4,496 +1.6% 10.65 US$47,882
2022-01-12 2022-01-10 B Purchase

Chief Executive Officer

Executive Director
5,504 +2.0%
10.10
US$55,590
5,504 +2.0% 10.10 US$55,590
2022-01-11 2022-01-07 B Purchase

See Remarks

Officer
9,295 +27.9%
9.44
US$87,745
9,295 +27.9% 9.44 US$87,745
2022-01-11 2022-01-07 B Purchase

See Remarks

Officer
705 +2.2%
8.97
US$6,324
705 +2.2% 8.97 US$6,324
2021-08-04 2021-08-02 B Purchase Non-Executive Director
76,923 +3.3%
13.00
US$999,999
76,923 +3.3% 13.00 US$999,999
2021-08-04 2021-08-02 B Purchase Non-Executive Director
615,384 +77.8%
13.00
US$7,999,992
615,384 +77.8% 13.00 US$7,999,992
2021-08-04 2021-08-02 B Purchase Large shareholder
615,384 +77.8%
13.00
US$7,999,992
615,384 +77.8% 13.00 US$7,999,992
2021-08-02 2021-07-29 B Purchase Large shareholder
806,000 +23.8%
13.00
US$10,478,000
806,000 +23.8% 13.00 US$10,478,000
Explore more

More insider trading research around Rallybio Corp